SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments More: Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma Source: News
read more
Partnership grants Lilly global rights to Alzstatin ACD680 More: Alzecure enters collaboration and with Lilly for Alzheimer’s project Source: News
read moreInclusion on the Pentagon’s 1260H list automatically makes WuXi AppTec one of the “biotechnology companies of concern” under the Biosecure Act. WuXi AppTec maintains that its place on the list was “clearly a mistake,” a spokesperson said. More: WuXi AppTec
read moreA combination of Merck’s islatravir and Gilead’s lenacapavir has succeeded in two phase 3 trials and is in line to become the first long-acting oral HIV treatment that can be taken weekly. More: Merck, Gilead score in effort to develop
read moreMerck & Co. and Gilead are pulling the plug on the phase 3 Evoke-03 trial evaluating Trodelvy, combined with Keytruda, as a first-line treatment in patients with PD-L1-high non-small cell lung cancer. More: As Gilead's Trodelvy stumbles in first-line lung
read moreThe LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing watchdog identifying eight breaches of its rules in the latest of a series of cases. More: AstraZeneca reprimanded over LinkedIn likes
read more© 1994 - 2026 B.M. Pharmaceuticals